STOCK TITAN

Moderna officer Stephen Hoge proposes $8.3M share sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) officer Stephen Hoge reported a proposed sale of 39,215 common shares, with an aggregate market value of $8,298,104.59 and an approximate sale date of November 17, 2026. The form also records that he acquired 39,215 shares through a cash-paid stock option exercise on November 17, 2026. A Rule 10b5-1 plan adoption date of June 15, 2026 is listed.

For the preceding three months, the form lists sales of 40,294 shares on September 14, 40,281 on September 15, 39,224 on October 14, 39,145 on October 15, and 39,160 on November 16, 2026.

Proposed sale shares 39,215 shares Common shares; approximate sale date November 17, 2026
Aggregate market value $8,298,104.59 Proposed sale
Gross proceeds $5,807,747.48 Sale on September 14, 2026
Gross proceeds $5,883,708.71 Sale on September 15, 2026
Gross proceeds $8,373,519.91 Sale on October 14, 2026
Gross proceeds $8,640,033.51 Sale on October 15, 2026
Gross proceeds $8,601,862.10 Sale on November 16, 2026
Stock Option Exercise financial
"Nature of Acquisition Transaction: Stock Option Exercise"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Aggregate Market Value financial
"Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does Stephen Hoge propose to sell in MRNA?

Stephen Hoge reported a proposed sale of 39,215 common shares, with an aggregate market value of $8,298,104.59. The approximate sale date is November 17, 2026.

What gross proceeds were reported for Stephen Hoge's recent MRNA share sales?

The listed gross proceeds were $5,807,747.48 on September 14, 2026; $5,883,708.71 on September 15; $8,373,519.91 on October 14; $8,640,033.51 on October 15; and $8,601,862.10 on November 16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading